Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

BACKGROUND: The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is only approved in patients with BRAF V600-positive melanoma, and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Exp Hematol Oncol
Egile Nagusiak: Marconcini, Riccardo, Galli, Luca, Antonuzzo, Andrea, Bursi, Simona, Roncella, Claudia, Fontanini, Gabriella, Sensi, Elisa, Falcone, Alfredo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2017
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5361706/
https://ncbi.nlm.nih.gov/pubmed/28344857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-017-0067-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak